SUTTON, England, April 4 -- Halting ovarian function by suppression or ablation offers little further benefit for most women already getting adjuvant tamoxifen with or without chemotherapy for early breast cancer, researchers here found.
The three adjuvant treatments had previously been shown to improve early breast cancer survival as monotherapies, but little long-term data had been available for combinations, said Judith Bliss, M.Sc., of the Institute of Cancer Research here, and colleagues.
So they conducted two large studies of combination adjuvant therapy for early breast cancer among women receiving five years of tamoxifen therapy. Both trials were started in the early 1990s before estrogen receptor status was routinely tested, Dr. Bliss and colleagues wrote in the April 4 Journal of the National Cancer Institute.
No comments:
Post a Comment